HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chapman, J. Articles by Michaelson, D. M. Search for Related Content PubMed PubMed Citation Articles by Chapman, J. Articles by Michaelson, D. M. Related Collections Alzheimer's disease

The effects of APOE genotype on age at onset and progression of neurodegenerative diseases

From the Departments of Physiology and Pharmacology (Drs. Chapman and Korczyn) and Neurology (Dr. Korczyn), Sackler Faculty of Medicine, and Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences (Dr. Michaelson), Tel Aviv University; and Department of Neurology, Hadasah Medical Center, Jerusalem (Dr. Karussis), Israel.

Address correspondence and reprint requests to Dr. D. M. Michaelson, Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69789, Israel; e-mail: dmichael{at}post.tau.ac.il

APOE genotype influences the age at onset of some neurodegenerative diseases such as AD and the rate of progression in others such as MS. The authors hypothesize that APOE genotype ubiquitously determines the efficacy of neuronal maintenance and repair in these diseases and that the seemingly divergent clinical effects are due to the stage of disease at which the diagnosis is made. Early diagnosis facilitates the measurement of effects on disease progression rate, whereas late diagnosis results in a marked effect of APOE genotype on disease onset.

This article has been cited by other articles:

				Z. Zhou, A. Hoke, D. R. Cornblath, J. W. Griffin, and M. Polydefkis APOE {epsilon}4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy Neurology, January 11, 2005; 64(1): 139 - 141. [Abstract] [Full Text] [PDF]

				N. De Stefano, M. L. Bartolozzi, B. Nacmias, V. Zipoli, M. Mortilla, L. Guidi, G. Siracusa, S. Sorbi, A. Federico, and M. P. Amato Influence of Apolipoprotein E {epsilon}4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis Arch Neurol, April 1, 2004; 61(4): 536 - 540. [Abstract] [Full Text] [PDF]

				P. M. Greenwood and R. Parasuraman Normal Genetic Variation, Cognition, and Aging Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 278 - 306. [Abstract] [PDF]

				D Karussis, D M Michaelson, N Grigoriadis, A D Korezyn, R Mizrachi-Koll, S Chapman, O Abramsky, and J Chapman Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis Multiple Sclerosis, October 1, 2003; 9(5): 476 - 480. [Abstract] [PDF]

				X.P. Wang, X.H. Wang, Y.C. Bao, and J.N. Zhou Apolipoprotein E genotypes in Chinese patients with Wilson's disease QJM, July 1, 2003; 96(7): 541 - 542. [Full Text] [PDF]

				M. Buttini, G.-Q. Yu, K. Shockley, Y. Huang, B. Jones, E. Masliah, M. Mallory, T. Yeo, F. M. Longo, and L. Mucke Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid beta Peptides But Not on Plaque Formation J. Neurosci., December 15, 2002; 22(24): 10539 - 10548. [Abstract] [Full Text] [PDF]

				K. G. Becker, J. Chapman, A. D. Korczyn, and D. M. Michaelson APOE genotype is a major predictor of long-term progression of disability in MS Neurology, December 1, 2001; 57(11): 2148 - 2149. [Full Text] [PDF]